Final Signatory

  • Portishead
  • Ck Group
CK Group are recruiting for a Final Signatory to join a company in the Pharmaceutical industry on a contract basis for 3 months. Location: Fully remote. Salary: 80.00- 108.00 per hour PAYE Final Signatory Role: To support our client's transformational change in how they engage with patients and physicians using high quality, engaging multi-channel content. To provide specialist Code advice and review, examination and certification services to the nominated internal team(s) to support the appropriate use of medicines and successful implementation of promotional and non-promotional materials, initiatives and programmes. To provide end-to-end medical partnership to the nominated internal team(s), from strategic conception of a programme to content development and approval. To maintain the highest standards for material in line with the ABPI Code of Practice, other applicable laws and regulations and internal policies, ensuring that content that is approved for use with UK health professionals, other relevant decision makers, patient groups, patients, the public and the media is appropriate and relevant. This role will support the VACCINES Business Unit. Your Background : Experience as a registered Final Signatory for pharmaceutical company/companies. Experience in reviewing materials in accordance with ABPI and UK regulations. Experience of partnering closely with commercial teams (eg marketing, access, corporate affairs). Experience with digital materials for HCPs and patients/public in the UK. Registered UK Pharmacist or Physician. Company: Our client is one of the world's premier innovative biopharmaceutical companies, discovering, developing and providing over 160 different medicines, vaccines and consumer healthcare products to help improve the lives of millions of people in the UK and around the world every year. Apply: It is essential that applicants hold entitlement to work in the UK. Please quote job reference 106106 in all correspondence. Please note: This role may be subject to a satisfactory basic Disclosure and Barring Service (DBS) check.